Colchicine
Approved · FDAAlso known as Colchicine-Probenecid, Colcrys, Gloperba, Lodoco+4 more
Colchicine-Probenecid, Colcrys, Gloperba, Lodoco, Mitigare, Colchicin, Colchicina, Colchicinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
CHMP positive opinion: Colchicine Agepha Pharma (EMA)
Indication expansion: COLCHICINE (NDA210942)
Colchicine's Role in Cardiovascular Disease Management.
Supplemental approval: COLCHICINE (NDA210942)
Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial.
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Approval: COLCHICINE (NDA210942)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple… Show full indicationShow less
Indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- American heart journal1
- Arteriosclerosis, thrombosis, and vascular biology1
- Circulation1
- JAMA network open1
- The Journal of neuroscience : the official journal of the Society for Neuroscience1
- The New England journal of medicine1
- Abe T1
- Adams H1
- Akasheh BF1
- Alexopoulos D1
- Alhaddad IA1
- Amerena J1
- Angelidis C1
- Angoulvant D1
- AHEPA Hospital1
- Alexandra Hospital1
- Athens Medical Center1
- Attikon Hospital1
- Bankstown-Lidcombe Hospital1
- Brigham and Women's Hospital1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.